Nivolumab serum concentration in metastatic melanoma patients could be related to outcome and enhanced immune activity: a gene profiling retrospective analysis.

Domenico MallardoDiana Giannarelli Maria Grazia VitaleDomenico GalatiGiusy TrillòAssunta EspositoMaria Antonietta IsgròGrazia D'AngeloLucia FestinoVito VanellaClaudia TrojanielloAndrew WhiteTeresa De CristofaroMichael BaileySandro PignataCorrado CaracòAntonella Petrillo Paolo MutoPiera MaiolinoAlfredo Budillon Sarah H Warren Ernesta Cavalcanti Paolo Antonio Ascierto

Published in: Journal for immunotherapy of cancer (2022)

In conclusion, these preliminary results show that in patients with MM, nivolumab concentration correlates with clinical outcomes and is associated with an increased expression of ICOS and other genes involved in the activation of T effectors cells.

Keyphrases

end stage renal disease
ejection fraction
induced apoptosis
chronic kidney disease
poor prognosis
peritoneal dialysis
genome wide
copy number
signaling pathway
gene expression
patient reported outcomes
patient reported
transcription factor
drug induced